Core Viewpoint - Genting New Year Limited (01952) successfully held a special shareholders' meeting on February 24, 2026, where all proposed resolutions were formally approved by shareholders [1] Group 1: Shareholder Meeting Outcomes - The special shareholders' meeting approved, confirmed, and ratified the commercialization service agreement signed with Haisen Biotechnology on December 11, 2025, and related transactions, supporting the company's future commercialization operations and business advancement [1] - The meeting also approved the granting of incentive arrangements to the company's management and adopted the 2026 share plan along with related authorization limits [1] - The high approval rate of these resolutions reflects investors' recognition of the company's strategic direction and governance, which will support the ongoing commercialization layout and long-term development strategy [1] Group 2: Strategic Partnerships - The collaboration with Haisen Biotechnology is expected to enhance the operational efficiency of the existing commercialization platform and accelerate the construction of product lifecycle and multi-channel coverage capabilities [1]

Core Viewpoint - Genting New Year Limited (1952.HK) successfully held a special shareholders' meeting on February 24, 2026, where all proposed resolutions were formally approved by shareholders [1] Group 1: Shareholder Meeting Outcomes - The special shareholders' meeting approved, confirmed, and ratified the commercialization service agreement signed with Haisen Biotechnology on December 11, 2025, along with related transactions to support the company's subsequent commercialization operations and business advancement [1] - The meeting also approved the granting of incentive arrangements to the company's management and adopted the 2026 share plan and related authorization limits [1] - The high approval rates for these resolutions reflect investors' recognition of the company's strategic direction and governance, which will support the ongoing commercialization layout and long-term development strategy [1] Group 2: Strategic Partnerships - The collaboration with Haisen Biotechnology is expected to enhance the operational efficiency of the existing commercialization platform and accelerate the construction of product lifecycle and multi-channel coverage capabilities [1]

Core Viewpoint - Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. (Zhonghui Bio) reported significant growth in its first interim performance announcement post-IPO, driven by the commercialization of its core product, the quadrivalent influenza virus subunit vaccine, Hui Er Kang Xin, which has shown remarkable commercial success and a reduction in losses compared to the previous year [1][2]. Financial Performance - The company achieved a revenue of 71.12 million yuan in the first half of the year, representing a year-on-year increase of 918.91% [1]. - Sales costs decreased by 18.3% year-on-year, leading to a gross margin increase to 85.5% [1]. - Losses narrowed by 22% year-on-year, indicating ongoing improvements in profitability [1]. Product Development and Market Penetration - The quadrivalent influenza virus subunit vaccine, Hui Er Kang Xin, is the first and only approved quadrivalent influenza subunit vaccine in China, with a 100% pass rate for batch release since its commercialization began in September 2023 [2]. - The product's market penetration has expanded to 30 provinces, with over 1,100 collaborations with district-level disease control centers [2]. - The company is advancing its full population coverage strategy, with plans for a vaccine targeting infants aged 6-35 months expected to receive approval by Q3 2025 [2]. Research and Development Pipeline - The company has a diverse pipeline of 11 vaccines, structured in a gradient development model from late-stage to preclinical [4]. - The rabies vaccine is in the final clinical stage, having completed Phase I trials with promising safety results [3]. - The company is also progressing in other high-demand areas, including the 23-valent pneumococcal polysaccharide vaccine and recombinant RSV vaccine, with various clinical trials underway [4]. Global Expansion Strategy - The company is building its international sales network, with plans to enter markets in Indonesia, Thailand, Uruguay, Canada, Singapore, Mexico, and Hong Kong by 2026 [5]. - In 2024, the company received registration in Macau and is progressing with registration in the Philippines [5]. - The company aims to leverage seasonal differences in flu outbreaks across regions to optimize production capacity [5]. Future Outlook - With the anticipated approval of the low-age indication for the influenza vaccine and the rabies vaccine entering Phase III clinical trials, the company is positioned to strengthen its competitive advantage in the high-growth vaccine sector [5].